期刊文献+

膀胱肿瘤标记物研究进展 被引量:2

下载PDF
导出
摘要 膀胱癌的发病率居泌尿系恶性肿瘤的第一位,据美国1998年的资料显示约60000患者患膀胱肿瘤,其中70%~80%为恶性肿瘤[1].
出处 《现代泌尿外科杂志》 CAS 2002年第3期181-183,共3页 Journal of Modern Urology
  • 相关文献

参考文献21

  • 1Lacombe L,Dalbangni G, Zhang ZF, et al. Overexpression of P53 protein in a high - risk population of patients with superficial bladde cancer before and after Bacillus Calmette - Guerin theropy: correla tion to clinical outcome. J Clin Oncol, 1996, 14:2646 - 2652.
  • 2Huber RP. Tumor markers in bladder cancer. Urology, 1984, 23(3Suppl): 10 - 14.
  • 3Sarosdy MF, De Vere White RW, Soloway MS. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol,1995, 154:379 - 383.
  • 4Ellis WJ, Blumenstein BA, Ishak LM. Clinical evaluation of the BAT TRAK assay and comparrison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology,1997,50:882 - 887.
  • 5Keesee SK, Briggman JV, Thill G, et al. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gone Expr.1996,6:189 - 214.
  • 6Soloway MS, Briggman V, Carpinito GA,et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring tranisitional cell carcinoma of the urinary tract following surgical treatment. J Urol, 1996, 156:363-367.
  • 7Lokeshwar VB, Obek C, Soloway MS, et al. Tumor associated hyaluronic acid:A new sensitive and specific urine marker for bladder cancer. Cancer Res,1997, 57:773 - 777.
  • 8Knudson W, Biswas C, Li XQ, et al. The role and regulation of tumor associated hyaluronan. Ciba Foundation Symp, 1989, 143:150-159.
  • 9Pham HT, Block NL, Lokeshwar VB. Tumor- derived hyaluronidise:A diagnostic urine marker for highgrade bladder cancer. Cancer Res, 1997,57: 778 - 783.
  • 10Lokeshwar VB, Block NL. HA- HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am, 2000, 27(1) :53 - 61.

同被引文献9

  • 1[1]Soloway MS, Briggman JV, Carpinito GA, et al. Use of a new marker, urinary NMP22 , in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment [J]. J Urol, 1996, 156(2 Pt 1): 363-367.
  • 2[2]Carpinito GA, Stadler WM, Briggman JV, et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract [J]. J Urol, 1996, 156(4): 1280-1285.
  • 3[4]Keesee SK, Briggman JV, Thill G, et al. Utilization of nuclear matrix protein for cancer diagnosis [J]. Crit Rev Eukaryot Gene Expr, 1996, 6(2-3):189-214.
  • 4[5]Sharma S, Zippc CD, Pandrangi L, et al. Exclusion criteria enhance the specificity and position predictive value of NMP22 and BTA stat [J]. J Urol, 1999,162(1):53-57.
  • 5[6]Serretta V, Presti DL, Vasile P, et al. Urinary NMP22 for the detection of recorrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients [J]. Urology, 1998, 52(5): 793-796.
  • 6Soloway MS,Briggman JV, Carpinmto GA,et al.Use of anew marker,urinary NMP22 ,in the detectiong of occult ot rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment[J].J Urol, 1996,156(2 pt1) :363.
  • 7Carpinito GA, stadler WM,briggman JV, et al.Urinary nuclear matrix protein as a marker for transitionas call carcinoma of the urinary tract[J].J Uorl, 1996,, 156(4): 1280.
  • 8Sharma S,Cippe CD,pandrang L,et al.Exclusion criteriaenhance the xpecificity and position predictive value of NMP22 and BTA stat[J].J Urol, 1999,162(1): 53.
  • 9Serretta V,Presti DL, Vasile P,et al.Urinary NMP22 for the detection of recurrence after traneurethral resetion of transitional cell carcinoma of the bladder.Experience on 137 patients[J].Urology, 1998, 52(5): 793.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部